Cerenis Therapeutics is a multinational biotechnology company dedicated to the discovery, development and commercialization of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. Therapies focused on increasing HDL (good cholesterol) represent the next frontier in the treatment of cardiovascular disease. Clinical evidence has demonstrated that HDL therapy can rapidly regress atherosclerotic plaque and elevating HDL can reduce cardiovascular morbidity and mortality. Cerenis is developing what has the potential to be the first-to-market and best-in-class recombinant HDL (CER-001). CER-001 has successfully completed Phase I. The product is designed to rapidly regress atherosclerotic plaque among patients at high risk of cardiovascular events. It is based on Cerenis’ multiple breakthroughs in the science of HDL, which have allowed the identification and development of highly potent and pure HDL particles.